Adherium Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Paul Mastoridis

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	8.8yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Paul Mastoridis

less than a year

Permanencia

Dr. Paul Mastoridis is Chief Executive Officer of Adherium Limited from February 2024. Paul Mastoridis has many years experience in the pharmaceutical industry, pioneering and leading digital solutions in...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Louis Panaccio	Executive Chairman of the Board	2.6yrs	AU$110.50k	1.01% A$ 92.0k
Daniel Kaplon	Chief Financial Officer	1.9yrs	AU$305.22k	sin datos
Paul Mastoridis	Chief Executive Officer	less than a year	sin datos	sin datos
Nilesh Ghatpande	VP of Engineering & Technology	less than a year	sin datos	sin datos
Cassandra Thomas	Vice President of People & Culture	less than a year	sin datos	sin datos
Michael Motion	Consultant	3.3yrs	AU$1.14m	sin datos
Zoe Park	Head of Software	less than a year	sin datos	sin datos
Nancy She	Head of Supply Chain and Procurement	less than a year	sin datos	sin datos
Michael Gormack	Head of Devices	less than a year	sin datos	sin datos
Emily Austin	Company Secretary	no data	sin datos	sin datos
John Wilson	Executive Medical Director	8yrs	AU$12.71k	sin datos

0.7yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de ADR no se considera experimentado ( 0.6 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Louis Panaccio	Executive Chairman of the Board	2.6yrs	AU$110.50k	1.01% A$ 92.0k
Bruce McHarrie	Independent Non-Executive Director	9.2yrs	AU$55.25k	0.049% A$ 4.4k
William Hunter	Independent Non-Executive Director	8.8yrs	AU$50.00k	0.027% A$ 2.5k
Jeremy Curnock-Cook	Independent Non-Executive Director	9.4yrs	AU$50.00k	0.024% A$ 2.2k
George Baran	Non-Executive Director	3.3yrs	AU$50.00k	0.99% A$ 90.0k

8.8yrs

Permanencia media

66yo

Promedio de edad

Junta con experiencia: La junta directiva de ADR se considera experimentada (8.7 años de antigüedad promedio).

Adherium Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Adherium Limited, Annual General Meeting, Nov 30, 2023

Adherium Limited Announces Resignation of Mark Licciardo as Joint Company Secretary

Adherium Limited Announces Executive Changes

Adherium Announces James Ward-Lilley Step Down from the Board

Adherium Limited, Annual General Meeting, Nov 29, 2022

Adherium Limited Appoints Daniel Kaplon as Chief Financial Officer, Effective 10 October 2022

Recent updates

New major risk - Revenue size

New major risk - Shareholder dilution

Adherium Limited has filed a Follow-on Equity Offering in the amount of AUD 1.57 million.

New major risk - Financial position

Forecast to breakeven in 2025

New major risk - Market cap size

Adherium Limited, Annual General Meeting, Nov 30, 2023

Full year 2023 earnings released: AU$0.002 loss per share (vs AU$0.005 loss in FY 2022)

New minor risk - Financial data availability

New major risk - Revenue size

Adherium Limited Announces Resignation of Mark Licciardo as Joint Company Secretary

Adherium Limited Announces Executive Changes

Adherium Limited Commences Production and Market Release of the New, Next Generation Ellipta Sensor

Adherium Limited Receives Australian Therapeutic Goods Administration Approval for Next Generation Sensors

Adherium Announces James Ward-Lilley Step Down from the Board

Adherium Limited Receives U.S. FDA 510(k) Clearance for GSK pMDI Inhaler Users to Remotely Monitor Physiological Parameters

Adherium Limited, Annual General Meeting, Nov 29, 2022

Adherium Limited Appoints Daniel Kaplon as Chief Financial Officer, Effective 10 October 2022

Full year 2022 earnings released: AU$0.005 loss per share (vs AU$0.017 loss in FY 2021)

Adherium Limited Submits FDA 510(K) Application for Next Generation Hailie Sensor for Teva MDI Inhalers

Adherium Limited Submits US FDA Application for Hailie for GSK pMDI inhalers

Adherium Limited Receives U.S. Food and Drug Administration Clearance for Hailie for Ellipta

Adherium Limited Announces Conclusion of Robert Spurr's Assignment as Interim CFO

Adherium Limited Releases Next Gen Platform Integration Services

Adherium Limited Submits US FDA 510(k) Application for Ellipta Inhaler Users to Connect to Hailie Platform with Physiological Parameters

Adherium Limited Announces Board Changes

Adherium Limited Announces That Manufacturing Started for Hailie® for Symbicort® Sensors with Physiological Parameters

Adherium Submits US FDS 510(k) Application for Next Generation Hailie Sensor with Physiological Measures

Adherium Limited announced that it expects to receive AUD 3 million in funding from Trudell Medical Limited, Bioscience Managers Pty Ltd

Independent Non-Executive Director has left the company

Adherium Limited Auditor Raises 'Going Concern' Doubt

Full year earnings released - AU$0.036 loss per share

CEO

Permanencia

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media

Promedio de edad